Search details
1.
Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection.
PLoS Pathog
; 19(11): e1011772, 2023 Nov.
Article
in English
| MEDLINE | ID: mdl-37943890
2.
Comparing the immune abnormalities in MIS-C to healthy children and those with inflammatory disease reveals distinct inflammatory cytokine production and a monofunctional T cell response.
Clin Immunol
; 259: 109877, 2024 02.
Article
in English
| MEDLINE | ID: mdl-38141746
3.
Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants.
J Virol
; 96(15): e0055822, 2022 08 10.
Article
in English
| MEDLINE | ID: mdl-35867572
4.
AstraZeneca COVID-19 vaccine induces robust broadly cross-reactive antibody responses in Malawian adults previously infected with SARS-CoV-2.
BMC Med
; 20(1): 128, 2022 03 28.
Article
in English
| MEDLINE | ID: mdl-35346184
5.
SARS-CoV-2 exposure in Malawian blood donors: an analysis of seroprevalence and variant dynamics between January 2020 and July 2021.
BMC Med
; 19(1): 303, 2021 11 19.
Article
in English
| MEDLINE | ID: mdl-34794434
6.
Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351).
N Engl J Med
; 384(22): 2161-2163, 2021 06 03.
Article
in English
| MEDLINE | ID: mdl-33826816
7.
Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.
PLOS Glob Public Health
; 4(4): e0002703, 2024.
Article
in English
| MEDLINE | ID: mdl-38603677
8.
Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination.
Front Immunol
; 14: 1231276, 2023.
Article
in English
| MEDLINE | ID: mdl-37600825
9.
Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection.
medRxiv
; 2023 Mar 15.
Article
in English
| MEDLINE | ID: mdl-36993404
10.
Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.
medRxiv
; 2023 Nov 20.
Article
in English
| MEDLINE | ID: mdl-38045321
11.
Enhanced neutralization potency of an identical HIV neutralizing antibody expressed as different isotypes is achieved through genetically distinct mechanisms.
Sci Rep
; 12(1): 16473, 2022 10 01.
Article
in English
| MEDLINE | ID: mdl-36182959
12.
SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity.
Cell Rep Med
; 3(2): 100510, 2022 02 15.
Article
in English
| MEDLINE | ID: mdl-35233544
13.
SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals.
Cell Host Microbe
; 30(6): 880-886.e4, 2022 06 08.
Article
in English
| MEDLINE | ID: mdl-35436444
14.
Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern.
Cell Rep Med
; 3(3): 100535, 2022 03 15.
Article
in English
| MEDLINE | ID: mdl-35474744
15.
HIV Broadly Neutralizing Antibodies Expressed as IgG3 Preserve Neutralization Potency and Show Improved Fc Effector Function.
Front Immunol
; 12: 733958, 2021.
Article
in English
| MEDLINE | ID: mdl-34566999
16.
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma.
Nat Med
; 27(4): 622-625, 2021 04.
Article
in English
| MEDLINE | ID: mdl-33654292
17.
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma.
bioRxiv
; 2021 Mar 01.
Article
in English
| MEDLINE | ID: mdl-33501446
18.
SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies.
bioRxiv
; 2021 Mar 11.
Article
in English
| MEDLINE | ID: mdl-33688657
Results
1 -
18
de 18
1
Next >
>>